Arrakis Therapeutics

OverviewSuggest Edit

Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. The Company develops an internal product pipeline of RNA-targeted small molecules focused on neurology, oncology, and rare genetic disorders. It offers scientific platforms, such as TRYST, MARS, PEARL-Seq, to identify tractable RNA targets, design drug molecules, and select candidates for clinical development. 
HQWaltham, MA, US

Latest Updates

Employees (est.) (Jan 2022)83(-1%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Arrakis Therapeutics

Michael Gilman

Michael Gilman

Chief Executive Officer, Director
Katrine Bosley

Katrine Bosley

Jakob Loven

Jakob Loven

Colleen Cuffaro

Colleen Cuffaro

Jennifer C. Petter

Jennifer C. Petter

Founder & Chief Innovation Officer
Raj Parekh

Raj Parekh

Show more

Arrakis Therapeutics Office Locations

Arrakis Therapeutics has an office in Waltham
Waltham, MA, US (HQ)
828 Winter St
Waltham, MA, US
35 Gatehouse Dr
Show all (2)

Arrakis Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Arrakis Therapeutics total Funding

$113 m

Arrakis Therapeutics latest funding size

$75 m

Time since last funding

3 years ago

Arrakis Therapeutics investors

Arrakis Therapeutics's latest funding round in April 2019 was reported to be $75 m. In total, Arrakis Therapeutics has raised $113 m
Show all financial metrics

Arrakis Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Arrakis Therapeutics Online and Social Media Presence

Embed Graph

Arrakis Therapeutics News and Updates

Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA

The Life Sciences team advised Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, on its $75 million Series B more

Arrakis Therapeutics Blogs

To the Builders Blazing our Path to Amazing Medicines

Arrakis has gone through many significant transitions since its founding in 2015. We’ve evolved and matured scientifically. We’ve added investors and partners. And, of course, people come and go. Today, we reach a bittersweet transition at Arrakis. We bid our head of research and employee #005, Jim …

Want A Great Team? Pick Great Leaders.

Back in 2015, I felt compelled to set out in a new direction in drug discovery. I was in my third year as VP of Chemistry for Celgene. This was a great gig – good people, good science. However, it required a level of travel that began to seem excessive. My kids were old enough […] The post Want A Gr…

Reaching cruising altitude: new discovery tools to target RNA

The majority of small molecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. In doing so, biological processes that rely on a specific target can be selectively modulated, ultim…

A new drug approval for the vanguard of RNA-targeted small molecules

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. We have overcome many obstacles on this mission, inventing new concepts and methods where necessary and re-engineering known concepts and methods where possible. But…

BioCentury This Week Podcast: Consummating a deal under lockdown: Roche and Arrakis

In a special podcast interview with BioCentury’s Editor in Chief Simone Fishburn, James Sabry, Global Head of Pharma Partnering at Roche and Mike Gilman CEO of Arrakis discuss consummating this deal while under lockdown of COVID-19. The post BioCentury This Week Podcast: <br>Consummating a dea…

Following our pole star to a transformative collaboration

It is an axiom of effective navigation, on earth or water or in interstellar space, that you need a fixed point to guide you. A beacon that shines clearly, never changes, never moves. If you drift off course, it pulls you back, keeps you on track. Locking your eyes on the pole star is critically […]…
Show more

Arrakis Therapeutics Frequently Asked Questions

  • When was Arrakis Therapeutics founded?

    Arrakis Therapeutics was founded in 2015.

  • Who are Arrakis Therapeutics key executives?

    Arrakis Therapeutics's key executives are Michael Gilman, Katrine Bosley and Jakob Loven.

  • How many employees does Arrakis Therapeutics have?

    Arrakis Therapeutics has 83 employees.

  • Who are Arrakis Therapeutics competitors?

    Competitors of Arrakis Therapeutics include ROPHIBIO, Onconetics Pharmaceuticals and Cytura Therapeutics.

  • Where is Arrakis Therapeutics headquarters?

    Arrakis Therapeutics headquarters is located at 828 Winter St, Waltham.

  • Where are Arrakis Therapeutics offices?

    Arrakis Therapeutics has an office in Waltham.

  • How many offices does Arrakis Therapeutics have?

    Arrakis Therapeutics has 2 offices.